1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Iconovo AB

Iconovo AB

SSTO:ICO
0.98
SEK
-0.04
(-3.84%)
-0.55EPS
100.98MMarket Cap
Oct 23Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.27
3.38
1.66
1.57
2.07
1.68
1.75
0.61
0.18
0.03
0.02
Basic EPS, GAAP
0.39
0.24
-0.6
-1.52
-1.99
-2.85
-4.93
-3.97
-2.57
-1.14
-0.55
Free Cash Flow per Basic Share
0.7
-1.41
-0.86
-2.68
-3.32
-4.02
-8.25
-5.32
-2.9
-1.21
-0.57
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.17
4.42
8.55
12.67
10.8
14.02
9.13
8.74
5.51
2.22
1.55
Tangible Book Value per Share
0.28
3.54
7.37
10.79
8.17
9.68
2.14
2.21
1.2
0.14
0.34
Basic Weighted Avg Shares
6
6
7
7
9
9
10
12
16
38
74
Sales/Revenue/Turnover
14
20
12
12
18
15
17
7
3
1
2
Operating Margin (%)
25.08
17.48
-34.44
-99.92
-92.69
-172.06
-282.53
-646.72
-1,400.06
-3,902.77
-2,199.46
Depreciation Expense
1
1
2
3
4
5
10
18
11
10
9
Net Income, GAAP
2
1
-4
-11
-17
-26
-48
-46
-41
-43
-41
Effective Tax Rate (%)
14.46
5.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
17.12
7.24
-36.06
-97.04
-96.3
-169.77
-281.39
-648.37
-1,402.23
-3,925.5
-2,215.09
Working Capital
5
24
51
91
66
90
9
17
18
- -
25
LT Debt
2
- -
- -
- -
- -
- -
8
5
4
1
1
Total Equity
9
33
64
109
93
137
89
114
129
118
149
Return on Invested Capital (%)
- -
11.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
6.92
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
6.96
-8.85
-13.18
-17
-22.77
-42.58
-45.28
-33.9
-35.09
-30.5

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
4
3
LT Borrowings
- -
- -
- -
LT Finance Leases
1
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
53
96
96
Market Capitalization
60
110
101

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
12
49
37
Cash, Cash Equivalents & STI
11
49
37
Accounts Receivable, Net
1
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
12
13
12
Payables & Accruals
- -
- -
- -
ST Debt
2
4
3
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
9.04%
-8.74%
Free Cash Flow
- -
19.72%
-1.04%
Net Income, GAAP
- -
25.43%
5.41%
Sales/Revenue/Turnover
- -
-36.37%
-62.35%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
- -
- -
1
3
2025
- -
- -
- -
1
1
2026
1
1
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.62
-0.6
-0.7
-0.59
-2.57
2025
-0.53
-0.2
- -
-0.24
-1.14
2026
-0.08
-0.1
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Anders Månsson
Full Time Employees
12
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Ideongatan 3 A-B Lund SN Sweden 223 70
IPO Date
Apr 6, 2018
Website
iconovo.se
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Iconovo AB (publ) specializes in the development and licensing of complete inhaled medicinal products in Sweden and for global markets. The company provides a unique combination of proprietary dry powder inhaler devices and in-house formulation expertise, enabling pharmaceutical partners to bring both generic and novel therapeutics to market. Their portfolio of patented inhaler platforms includes ICOres, a flexible multi-dose device designed to accommodate various medications, ICOcap, a capsule-based dry powder inhaler, ICOone, a single-dose disposable inhaler, which also has a nasal variant, ICOone Nasal, and ICOpre, a pre-metered multi-dose system. Iconovo collaborates with international pharmaceutical companies, offering comprehensive development services, from initial concept through to manufacturing of clinical trial materials and technical documentation. Its revenue model is based on development fees, technology access fees for exclusive rights to drug-inhaler combinations, and royalties on product sales. Current key projects involve a partnership with Amneal Pharmaceuticals for a generic version of Symbicort, utilizing the ICOres platform, which has shown positive clinical pilot study results, and ongoing formulation development with Kiox Pharma for an inhaled treatment for interstitial lung disease using ICOcap. The company has also initiated the strategic development of intranasally inhaled semaglutide for obesity and metabolic diseases in its ICOone Nasal device. Iconovo aims to reduce development time and risk for its partners, positioning itself as a leader in innovative inhalation therapy. Founded in 2013, Iconovo AB (publ) is headquartered in Lund, Sweden.